Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1987-03-13
1990-03-27
Shen, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514340, 546275, 548240, 548243, 548245, 548246, A61K 3142, A61K 3144, A61K 3140, A61K 31405, C07D26104, C07D23364, C07D20908, C07D20932, C07D20940
Patent
active
049121200
ABSTRACT:
The present invention is directed to certain 3,5 substituted, 4,5-dihydroisoxazoles, and methods for their use. These compounds are transgulatminase inhibitors, and are particularly effective in the inhibition of epidermal transglutaminase and the treatment of acne.
REFERENCES:
patent: 4276299 (1981-06-01), Della Bella et al.
patent: 4277485 (1981-07-01), Durant et al.
patent: 4283403 (1981-08-01), Davenport
patent: 4298744 (1981-11-01), Kelly et al.
patent: 4451476 (1984-05-01), Diana
patent: 4497812 (1985-02-01), Creuzet et al.
patent: 4499090 (1985-02-01), Creuzet et al.
P. A. Wade, et al., Tetrahedron Letters, vol. 23 (No. 44) 4563-4566 (1982) Cyanogen Chloride N-Oxide Cycloaddititions, A simple short route to AT-125.
Chemical Abstracts, vol. 78 (No. 13), 2 Apr. 1973, p. 466, Abstract No. 84476F.
Schasteen et al., Biochemical and Biophsical Res. comm. 112(2), 564-70 (1983).
Tso et al., J. Biol Chem., 255(14) 6734-38(1980).
McGuire et al., Investigational New Drugs, 4, 49-52(1986).
Lui et al., Biochem. Pharamacology, 31(21), 3469-3473(1982).
Poster et al., Cancer Clin. Trials, 4, 327-30(1981).
Maroun et al., Cancer Treatment Reports, 68 (9), 1121-23(1984).
Jayaram et al., Cancer Research, 45, 207-12(1985).
Denton et al., Life Sciences, 30(13), 1073-80(1982).
McGovern et al., Cancer Research, 45, 4460-63(1985).
"Information Update" Drugs of the Future, 8(4), 351-54(1983).
"Information Update" Drugs of the Future, 4(4) 252-54(1979).
Martin et al., The J. of Antibiotics, 34(4) 459-61(1981).
Capraro et al., J. Biological Chem. 260(6), 3408-12(1985).
Jayaram et al. Cancer Research, 45, 207-12(1985).
Weber et al., Adv. in Enzyme Regulations, 22, 69-93(1984).
Earhart et al., Adv. in Enzyme Regulations, 24, 179-243(1986).
Carl et al., Proc. Natl. Acad. Sci. USA. 77(4) 2224-28(1980).
Cakravarty et al., J. Med. Chem. 26, 638-44(1983).
Wade et al., Tetrahedron, 40(3), 601-11(1984).
De Young et al., J. of Invest. Dermatology 82(3), 275-79(1984).
Castelhano Arlindo L.
DeYoung Lawrence M.
Krantz Alexander
Pliura Diana H.
Venuti Michael C.
Johnson Lester E.
Moran Tom M.
Shen Cecilia
Syntex (U.S.A.) Inc.
Toth Liza K.
LandOfFree
3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1651363